Life Sciences Tools and Services
Company Overview of ShangPharma Corporation
ShangPharma Corporation, through its subsidiaries, operates as a pharmaceutical and biotechnology research and development outsourcing company. It offers various integrated services across the drug discovery and development process to international and Chinese pharmaceutical and biotechnology companies, and academic and research institutions. The company’s services include discovery chemistry, discovery biology and preclinical development, pharmaceutical development, and biologics services. Its discovery chemistry services consist of medicinal chemistry, synthetic chemistry, library generation, and analytical chemistry; and discovery biology and preclinical development services comprise assa...
No 5 Building 998 Halei Road
Zhangjiang Hi-Tech Park Pudong New Area
Founded in 2002
Key Executives for ShangPharma Corporation
President and Chief Scientific Officer
Compensation as of Fiscal Year 2014.
ShangPharma Corporation Key Developments
ShangPharma Corporation Appoints Mitchell Reff as Chief Biologics Officer
Jan 13 14
ShangPharma Corporation announced that Dr. Mitchell Reff has joined the company as Chief Biologics Officer. He joined Idec Pharmaceuticals as head of molecular biology in 1990. Dr. Reff had a distinguished 21 year career at Idec, and later at Biogen Idec. He was Vice President Discovery Oncology at Biogen Idec running multiple bicoastal oncology groups developing small molecule and recombinant protein therapeutic molecules for oncology and delivered 6 novel oncology drugs into clinical trials in 5 years. Dr. Reff is well-recognized in the pharmaceutical and research community having been listed as an inventor on approximately 29 patents and patent applications, and as an author in nearly 100 scientific publications and presentations.
ShangPharma Corporation Appoints Art Taveras as President and Chief Scientific Officer
Oct 25 13
ShangPharma Corporation announced that Dr. Art Taveras will join the company as President and Chief Scientific Officer (CSO). As President and CSO, Dr. Taveras will establish the company as the premiere Drug Discovery and Development partner of Pharmaceutical and Biotechnology companies worldwide. Prior to joining the company, Dr. Taveras was Vice President Small Molecules Drug Discovery, Vice President Chemistry R&D, and Vice President CMC Development at Biogen Idec. Prior to joining ShangPharma, Dr. Taveras was Vice President Small Molecules Drug Discovery, Vice President Chemistry R&D, and Vice President CMC Development at Biogen Idec, leading the discovery and CMC development of neurology, immunology and oncology drug candidates at its multiple sites and partnerships in the U.S. and abroad. Before Biogen Idec, Dr. Taveras was Vice President of Drug Discovery and CMC Development at Alantos Pharmaceuticals.
ShangPharma Corporation, Special/Extraordinary Shareholders Meeting, Mar 20, 2013
Feb 25 13
ShangPharma Corporation, Special/Extraordinary Shareholders Meeting, Mar 20, 2013., at 10:00 China Standard Time. Location: 42nd Floor, Edinburgh Tower. Agenda: To consider on the proposal to authorize and approve the previously announced agreement and plan of merger, dated December 21, 2012, among the company, ShangPharma Holdings Limited, ShangPharma Parent Limited and ShangPharma Merger Sub Limited.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|